Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Altimmune Inc (ALT)
NASDAQ:ALT
Holding ALT?
Track your performance easily
Earnings Data
Report Date
Mar 27, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.34Last Year’s EPS
-$0.54Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 12, 2024
|% Change Since: 12.24%
|Next Earnings Date:Mar 27, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in the clinical development of pemvidutide, including successful trial enrollments and FDA alignment on Phase III plans. However, financial challenges such as increased net loss and decreased cash reserves were noted. Overall, the sentiment leans positive due to the strategic advancements and strong cash position to support future developments.Company Guidance
During the Altimmune Q3 2024 earnings call, significant guidance was provided, highlighting key metrics and milestones. The company reported that its cash and cash equivalents stood at approximately $139.4 million, projecting this to fund operations into the first half of 2026. The Phase IIb IMPACT trial for pemvidutide in MASH is fully enrolled with efficacy data expected in Q2 2025. The strategic alignment with the FDA was achieved for a comprehensive Phase III obesity program, including four pivotal VELOCITY studies aiming to enroll around 5,000 subjects. These trials will evaluate the effects of pemvidutide on body weight and other endpoints over a 60-week period. Altimmune is also exploring three additional indications for pemvidutide, with an IND submission expected by the end of 2024. The company disclosed R&D expenses of $19.8 million and a net loss of $22.8 million for the quarter.Successful Completion of Phase IIb IMPACT Trial Enrollment
The Phase IIb IMPACT trial for pemvidutide in MASH is fully enrolled, with top-line efficacy data expected in Q2 2025. This marks a significant milestone in the development of pemvidutide.
FDA Alignment on Phase III Registrational Program
Altimmune achieved alignment with the FDA on a comprehensive Phase III registrational program for obesity, which includes four pivotal VELOCITY trials designed to leverage the key attributes of pemvidutide.
Strong Cash Position
Altimmune ended Q3 2024 with $139.4 million in cash, cash equivalents, and short-term investments, projected to fund operations into the first half of 2026.
Expansion of R&D Programs
Strategic decision to expand R&D investments into three additional indications for pemvidutide, with the first IND submission planned by the end of 2024.
---
ALT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ALT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 12, 2024 | $7.35 | $9.49 | +29.12% |
| Aug 08, 2024 | $5.50 | $6.33 | +15.09% |
| May 09, 2024 | $7.16 | $7.72 | +7.82% |
| Mar 27, 2024 | $8.65 | $8.89 | +2.77% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Altimmune Inc (ALT) report earnings?
Altimmune Inc (ALT) is schdueled to report earning on Mar 27, 2025, TBA Not Confirmed.
What is Altimmune Inc (ALT) earnings time?
Altimmune Inc (ALT) earnings time is at Mar 27, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ALT EPS forecast?
ALT EPS forecast for the fiscal quarter 2024 (Q4) is -$0.34.
---